APLS · As filed with the SEC
Apellis Pharmaceuticals income statement, by fiscal year
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Income/(Loss) · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Revenue: | ||||
| Revenue | 1,003,782,000 | 781,367,000 | 396,591,000 | 75,422,000 |
| Licensing and other revenue | 314,399,000 | 71,413,000 | 30,310,000 | 10,330,000 |
| Product revenue, net | 689,383,000 | 709,954,000 | 366,281,000 | 65,092,000 |
| Operating expenses: | ||||
| Cost of sales | 102,236,000 | 117,723,000 | 58,510,000 | 5,636,000 |
| Research and development | 295,854,000 | 327,570,000 | 354,387,000 | 387,236,000 |
| Selling, general and administrative | 550,265,000 | 501,053,000 | — | — |
| General and administrative | — | — | 500,815,000 | 277,163,000 |
| Total operating expenses: | 948,355,000 | 946,346,000 | 913,712,000 | 670,035,000 |
| Net operating income/(loss) | 55,427,000 | (164,979,000) | (517,121,000) | (594,613,000) |
| Loss on conversion of debt | — | — | — | (32,890,000) |
| Loss on extinguishment of development liability | — | (1,949,000) | — | — |
| Interest income | 13,143,000 | 12,773,000 | 20,933,000 | 8,914,000 |
| Interest expense | — | — | (29,581,000) | (32,626,000) |
| Interest expense | (44,327,000) | (40,391,000) | — | — |
| Other expense, net | (133,000) | (2,170,000) | (727,000) | (288,000) |
| Net income/(loss) before taxes | 24,110,000 | (196,716,000) | (526,496,000) | (651,503,000) |
| Income tax expense | 1,722,000 | 1,162,000 | 2,132,000 | 669,000 |
| Net income/(loss) | 22,388,000 | (197,878,000) | (528,628,000) | (652,172,000) |
| Other comprehensive income/(loss): | ||||
| Unrealized (loss)/gain on marketable securities | — | — | — | (1,000) |
| Unrealized (loss)/gain on pension plans | — | 591,000 | (2,618,000) | 1,646,000 |
| Unrealized gain/(loss) on pension plans | 107,000 | — | — | — |
| Foreign currency translation | 1,098,000 | (357,000) | (49,000) | (430,000) |
| Total other comprehensive income/(loss) | 1,205,000 | 234,000 | (2,667,000) | 1,215,000 |
| Comprehensive income/(loss), net of tax | 23,593,000 | (197,644,000) | (531,295,000) | (650,957,000) |
| Net income/(loss) per common share - basic | 0.18 | (1.6) | (4.45) | (6.15) |
| Net income/(loss) per common share - diluted | 0.2 | (1.6) | (4.45) | (6.15) |
| Weighted-average number of common shares used in net income/(loss) per common share - basic | 126,145,000 | 123,905,000 | 118,678,000 | 106,114,000 |
| Weighted-average number of common shares used in net income/(loss) per common share - diluted | 129,855,000 | 123,905,000 | 118,678,000 | 106,114,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.